<table class="infobox infobox-gene">
<tr><th class="infobox-header" colspan="2">DYRK1B</th></tr>
<tr><td class="label">Full Name</td><td>Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B</td></tr>
<tr><td class="label">Chromosome</td><td>19p13.12</td></tr>
<tr><td class="label">NCBI Gene ID</td><td><a href="https://www.ncbi.nlm.nih.gov/gene/9149" target="_blank">9149</a></td></tr>
<tr><td class="label">Ensembl ID</td><td>ENSG00000105204</td></tr>
<tr><td class="label">OMIM ID</td><td>604556</td></tr>
<tr><td class="label">UniProt ID</td><td><a href="https://www.uniprot.org/uniprot/Q9Y463" target="_blank">Q9Y463</a></td></tr>
<tr><td class="label">Associated Diseases</td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [PSP](/diseases/psp), Metabolic Syndrome, Tauopathies</td></tr>
</table>
DYRK1B — Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B
Overview
DYRK1B (also known as MIRK — Minibrain-Related Kinase) encodes a dual-specificity protein kinase belonging to the DYRK family, which phosphorylates substrates on both serine/threonine and tyrosine residues. DYRK1B is the closest paralog of [DYRK1A](/genes/dyrk1a), one of the most important kinases in Down syndrome-associated [Alzheimer's disease](/diseases/alzheimers-disease). While DYRK1A has been extensively studied for its role in [tau](/genes/mapt) hyperphosphorylation and [amyloid](/proteins/amyloid-beta) processing, DYRK1B has received less attention despite sharing key substrate specificities and potentially contributing to tauopathy through complementary mechanisms[@becker2011].
DYRK1B is expressed in the brain and is catalytically active at the time of translation through an intramolecular autophosphorylation mechanism. Its activation of quiescence programs, roles in [GSK-3β](/genes/gsk3b) signaling, and direct tau phosphorylation activity make it relevant to neurodegenerative disease — particularly [progressive supranuclear palsy](/diseases/psp) (PSP) and other primary tauopathies where tau kinase inhibition is an active therapeutic strategy[@deng2011].
Gene Structure and Expression
DYRK1B is located on chromosome 19p13.12 and encodes a 629-amino acid protein kinase. The protein contains:
- N-terminal DYRK homology (DH) box (residues 70-88): Unique to the DYRK family, required for proper folding and activation
- Kinase domain (residues 112-445): Catalytic domain with dual-specificity activity. Contains the characteristic YxY motif in the activation loop — the second tyrosine (Y273) undergoes autophosphorylation during translation, which is required for kinase activation
- PEST domain (residues 481-580): Contains PEST sequences that regulate protein turnover
- C-terminal region: Contains a nuclear localization signal and regulatory domains
DYRK1B expression in the adult brain is moderate compared to DYRK1A, with highest levels in the [hippocampus](/brain-regions/hippocampus), [cerebral cortex](/brain-regions/cerebral-cortex), and [cerebellum](/brain-regions/cerebellum). Unlike DYRK1A, DYRK1B expression is enriched in quiescent cells and non-dividing [neurons](/entities/neurons), consistent with its role in promoting G0 arrest and cellular quiescence[@ashford2016].
Function
Kinase Activity and Substrate Specificity
DYRK1B is a proline-directed kinase with substrates overlapping those of DYRK1A:
- Tau phosphorylation: DYRK1B directly phosphorylates [tau](/proteins/tau) at multiple sites including Thr212, which primes tau for subsequent [GSK-3β](/genes/gsk3b)-mediated phosphorylation at Ser208 — a critical step in generating the pathological AT8 and PHF-1 epitopes characteristic of tauopathy
- Cyclin D1: Phosphorylation of cyclin D1 at Thr286, targeting it for nuclear export and proteasomal degradation, enforcing cell cycle exit
- p27Kip1: Stabilization of the CDK inhibitor p27, maintaining quiescence
- [DREAM complex](/proteins/dream-complex): Phosphorylation of LIN52 at Ser28, promoting DREAM complex assembly and transcriptional repression of cell cycle genes
Cell Cycle Regulation and Quiescence
DYRK1B's primary physiological function involves maintaining cellular quiescence:
- G0 maintenance: DYRK1B promotes entry into and maintenance of G0 quiescence in differentiated cells, including neurons
- Anti-proliferative signaling: Through cyclin D1 degradation and p27 stabilization
- Aberrant cell cycle re-entry prevention: In post-mitotic neurons, DYRK1B helps prevent pathological cell cycle re-entry, which has been implicated as a death pathway in [Alzheimer's disease](/diseases/alzheimers-disease)[@herrup2007]
DYRK1B has significant metabolic functions:
- Hedgehog signaling: DYRK1B promotes [GLI1](/genes/gli1) nuclear import, activating Hedgehog target genes
- [mTOR](/mechanisms/mtor-signaling-pathway) pathway: DYRK1B can modulate [mTOR](/genes/mtor) signaling through effects on upstream regulators
- Lipid metabolism: Gain-of-function DYRK1B mutations cause familial metabolic syndrome (AOMS3), linking kinase hyperactivity to metabolic disease[@keramati2014]
GSK-3β Priming Function
A critical function in neurodegeneration:
- Priming kinase: DYRK1B phosphorylates tau at sites that prime subsequent phosphorylation by [GSK-3β](/genes/gsk3b), the most important tau kinase
- Synergistic hyperphosphorylation: The DYRK1B → [GSK-3β](/entities/gsk3-beta) sequential phosphorylation cascade generates heavily phosphorylated tau species that are prone to aggregation into paired helical filaments (PHFs)
- Functional redundancy with DYRK1A: DYRK1B may partially compensate when DYRK1A is inhibited, posing a challenge for tau kinase-targeted therapeutics[@ferrer2005]
Disease Associations
Alzheimer's Disease
DYRK1B contributes to AD pathogenesis through several mechanisms:
- Tau hyperphosphorylation: Direct phosphorylation of tau and priming for GSK-3β creates the pathological tau species that form neurofibrillary tangles
- Cell cycle re-entry: Loss of DYRK1B-mediated quiescence may allow aberrant cell cycle re-entry in neurons, a process observed in AD brains that precedes neuronal death
- [RCAN1](/genes/rcan1) regulation: DYRK1B, like DYRK1A, can phosphorylate RCAN1 (Regulator of Calcineurin 1), modulating calcineurin-[NFAT](/proteins/nfat-protein) signaling in neurons
- Compensatory upregulation: When DYRK1A inhibitors are tested therapeutically, DYRK1B may be upregulated as a compensatory tau kinase, potentially limiting treatment efficacy[@ryoo2007]
Progressive Supranuclear Palsy and Tauopathies
DYRK1B is relevant to primary tauopathies:
- 4R-tau phosphorylation: [PSP](/diseases/psp) and [corticobasal degeneration](/diseases/corticobasal-degeneration) are characterized by [4R-tau](/proteins/4r-tau) pathology. DYRK1B's tau phosphorylation activity is relevant to the tau isoform composition in these diseases
- [MAPT](/genes/mapt) H1 haplotype: PSP is strongly associated with the [MAPT](/proteins/tau) H1 haplotype, which increases tau expression. DYRK1B-mediated phosphorylation of this excess tau may contribute to disease
- Brainstem vulnerability: DYRK1B expression in brainstem nuclei vulnerable in PSP (substantia nigra, subthalamic nucleus, pontine tegmentum) positions it as a contributor to regional tau pathology
- Therapeutic target: Pan-DYRK inhibitors (targeting both DYRK1A and DYRK1B) may be more effective than DYRK1A-selective inhibitors for tauopathy treatment[@wegiel2011]
Gain-of-function mutations in DYRK1B cause autosomal dominant metabolic syndrome type 3 (OMIM #615812):
- R102C mutation: Activating mutation causing central obesity, type 2 diabetes, hypertension, and coronary artery disease
- H90P mutation: Another activating mutation with similar metabolic phenotype
- Brain-body axis: The metabolic syndrome phenotype raises questions about whether DYRK1B hyperactivity in the brain could contribute to metabolic risk factors for neurodegeneration[@keramati2014]
Therapeutic Implications
DYRK1B as a Drug Target
- Pan-DYRK inhibitors: Compounds such as harmine, INDY, leucettine L41, and AZ191 inhibit both DYRK1A and DYRK1B. Dual inhibition may be necessary to prevent compensatory tau phosphorylation
- DYRK1B-selective inhibitors: AZ191 shows some selectivity for DYRK1B over DYRK1A, enabling studies of DYRK1B-specific functions
- Combination strategies: DYRK1B inhibition combined with [GSK-3β](/genes/gsk3b) inhibition (e.g., [tideglusib](/therapeutics/tau-targeted-therapeutics)) could block the sequential priming cascade more effectively
- PROTAC approach: Targeted protein degradation of DYRK1B using PROTAC technology is under investigation[@abbassi2015]
Challenges
- Kinase selectivity: The DYRK family shares high kinase domain similarity, making isoform-selective inhibition difficult
- Metabolic side effects: DYRK1B inhibition could potentially cause metabolic derangements given its role in glucose and lipid metabolism
- Compensatory mechanisms: Other proline-directed kinases ([CDK5](/genes/cdk5), [CLK1](/genes/clk1)) may compensate for DYRK1B loss
Key Research Findings
- Lochhead et al. (2005) elucidated the DYRK family activation mechanism through co-translational autophosphorylation[@lochhead2005]
- Keramati et al. (2014) identified gain-of-function DYRK1B mutations causing metabolic syndrome[@keramati2014]
- Ashford et al. (2014) characterized DYRK1B's role in the DREAM complex and transcriptional repression[@ashford2016]
- Ferrer et al. (2005) demonstrated DYRK1A/1B overexpression in tauopathy-affected brain regions[@ferrer2005]
Pathway & Interaction Diagram
Interactive diagram showing DYRK1B's key relationships in the SciDEX knowledge graph (7 connections shown).
Mermaid diagram (expand to render)
See Also
- [DYRK1A](/genes/dyrk1a) — Primary paralog, major tau kinase in Down syndrome-AD
- [GSK3B](/genes/gsk3b) — Key downstream tau kinase primed by DYRK1B
- [CDK5](/genes/cdk5) — Another proline-directed tau kinase
- [MAPT](/genes/mapt) — Tau gene, substrate of DYRK1B
- [Tau Hyperphosphorylation](/mechanisms/tau-hyperphosphorylation) — Pathway involving DYRK1B
- [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)
External Links
- [NCBI Gene: DYRK1B](https://www.ncbi.nlm.nih.gov/gene/9149)
- [UniProt: Q9Y463](https://www.uniprot.org/uniprot/Q9Y463)
- [GeneCards: DYRK1B](https://www.genecards.org/cgi-bin/carddisp.pl?gene=DYRK1B)
- [OMIM: 604556](https://omim.org/entry/604556)
- [PhosphoSitePlus: DYRK1B](https://www.phosphosite.org/proteinAction.action?id=4987)
References
[Becker W, Sippl W, Activation, regulation, and inhibition of DYRK1A (2011)](https://pubmed.ncbi.nlm.nih.gov/21461681/)
[Deng X et al, Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 (2011)](https://pubmed.ncbi.nlm.nih.gov/21145500/)
[Ashford AL et al, Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome (2016)](https://pubmed.ncbi.nlm.nih.gov/25620560/)
[Herrup K, Yang Y, Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? (2007)](https://pubmed.ncbi.nlm.nih.gov/17521575/)
[Keramati AR et al, A form of the metabolic syndrome associated with mutations in DYRK1B (2014)](https://pubmed.ncbi.nlm.nih.gov/24449231/)
[Ferrer I et al, Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models (2005)](https://pubmed.ncbi.nlm.nih.gov/15758156/)
[Ryoo SR et al, DYRK1A-mediated hyperphosphorylation of Tau: a functional link between Down syndrome and Alzheimer disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17606904/)
[Wegiel J et al, Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome (2011)](https://pubmed.ncbi.nlm.nih.gov/21192935/)
[Abbassi R et al, DYRK1A in neurodegeneration and cancer: molecular basis and clinical implications (2015)](https://pubmed.ncbi.nlm.nih.gov/26032971/)
[Lochhead PA et al, Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs (2005)](https://pubmed.ncbi.nlm.nih.gov/15880548/)Pathway Diagram
The following diagram shows the key molecular relationships involving DYRK1B — Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)